Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod open-label extension in primary progressive multiple sclerosis
NL-OMON39777Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fingolimod in primary progressive multiple sclerosis (PPMS), sponsored by Novartis. Primary endpoint: Adverse events. Started Apr 2013; status: active, not recruiting.
02
Drugs
fingolimod
03
Conditions
primary progressive multiple sclerosis (PPMS)
Beyond the preview
Go deeper on NL-OMON39777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39777.